Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 29, 2018
AZURRX BIOPHARMA, INC.
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2) ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 5.02
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
On May 29, 2018, AzurRx BioPharma,
Inc. (the “Company”) appointed Dr. James E. Pennington to
serve as the Company’s Chief Medical Officer. A copy of the
press release announcing Dr. Pennington’s appointment is
attached to this Current Report on Form 8-K as Exhibit
99.1
Dr.
Pennington, age 75, has over 30 years of experience in the
pharmaceutical industry. Prior to joining the Company, Dr.
Pennington served as Senior Clinical Fellow from 2010 to 2018 and
Executive Vice President and Chief Medical Officer from 2007 to
2010 at Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH). From 2004 to
2007, Dr. Pennington served as Executive Vice President and Chief
Medical Officer at CoTherix, Inc., and has served in various
executive positions at a number of other pharmaceutical companies,
including InterMune Inc., Shaman Pharmaceuticals and Bayer
Corporation. In addition, Dr. Pennington has sat on several
editorial boards, and has authored numerous original research
publications and reviews. Dr. Pennington is currently a Clinical
Professor of Medicine with the University of California San
Francisco, where he has taught since 1986. Prior to that, he was a
professor at Harvard Medical School. Dr. Pennington received a
Bachelor of Arts from the University of Oregon and a Doctor of
Medicine from the University of Oregon School of Medicine, and is
Board Certified in internal medicine and infectious
diseases.
Dr. Pennington has no direct or indirect material interest in any
transaction required to be disclosed pursuant to Item 404(a)
of Regulation S-K, has no arrangement or
understanding between him and any other person required to be
disclosed pursuant to Item 401(b) of Regulation S-K, and
has no family relationships required to be disclosed pursuant to
Item 401(d) of Regulation S-K.
Item
9.01
Financial
Statements and Exhibits
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AzurRx BioPharma, Inc.
|
|
|
|
|
|
|
|
|
Date: June 1,
2018
|
By:
|
/s/ Johan M.
Spoor
|
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
|
Title: Chief Executive Officer
|
|
Exhibit Index
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Press Release issued by AzurRx BioPharma, Inc., dated May 30,
2018
|
|